Inhibition_NN
of_IN
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
replication_NN
in_FW
vitro_FW
by_IN
a_DT
novel_JJ
combination_NN
of_IN
anti-Tat_JJ
single-chain_JJ
intrabodies_NNS
and_CC
NF-kappa_NN
B_NN
antagonists_NNS
._.

Human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
-LRB-_-LRB-
HIV-1_NN
-RRB-_-RRB-
Tat_NN
,_,
an_DT
early_JJ
regulatory_JJ
protein_NN
that_WDT
is_VBZ
critical_JJ
for_IN
viral_JJ
gene_NN
expression_NN
and_CC
replication_NN
,_,
transactivates_VBZ
the_DT
HIV-1_NN
long_JJ
terminal_JJ
repeat_NN
-LRB-_-LRB-
LTR_NN
-RRB-_-RRB-
via_IN
its_PRP$
binding_NN
to_TO
the_DT
transactivation_NN
response_NN
element_NN
-LRB-_-LRB-
TAR_NN
-RRB-_-RRB-
and_CC
,_,
along_IN
with_IN
other_JJ
cellular_JJ
factors_NNS
,_,
increases_VBZ
viral_JJ
transcription_NN
initiation_NN
and_CC
elongation_NN
._.

Tat_NN
also_RB
superactivates_VBZ
the_DT
HIV-1_NN
promoter_NN
through_IN
a_DT
TAR-independent_JJ
mechanism_NN
,_,
including_VBG
tumor_NN
necrosis_NN
factor_NN
alpha-induced_JJ
and_CC
protein_NN
kinase_NN
C_NN
-LRB-_-LRB-
PKC_NN
-RRB-_-RRB-
-_:
dependent_JJ
activation_NN
of_IN
NF-kappa_NN
B_NN
,_,
and_CC
inhibitors_NNS
of_IN
Tat_NN
and_CC
NF-kappa_NN
B_NN
cooperatively_RB
down-regulate_VBP
this_DT
Tat-mediated_JJ
LTR_NN
superactivation_NN
._.

In_IN
this_DT
study_NN
,_,
a_DT
combined_JJ
pharmacologic_JJ
and_CC
genetic_JJ
strategy_NN
using_VBG
two_CD
PKC_NN
-LRB-_-LRB-
NF-kappa_NN
B_NN
-RRB-_-RRB-
inhibitors_NNS
,_,
pentoxifylline_NN
-LRB-_-LRB-
PTX_NN
-RRB-_-RRB-
and_CC
Go-6976_NN
,_,
and_CC
a_DT
stably_RB
expressed_VBN
anti-Tat_JJ
single-chain_JJ
intracellular_JJ
antibody_NN
-LRB-_-LRB-
sFv_NN
intrabody_NN
-RRB-_-RRB-
was_VBD
employed_VBN
to_TO
obtain_VB
cooperative_JJ
inhibition_NN
of_IN
both_CC
HIV-1_NN
LTR-driven_JJ
gene_NN
expression_NN
and_CC
HIV-1_NN
replication_NN
._.

Treatment_NN
of_IN
cells_NNS
with_IN
PTX_NN
and_CC
Go-6976_NN
resulted_VBD
in_IN
cooperative_JJ
inhibition_NN
of_IN
both_CC
HIV-1_NN
LTR-driven_JJ
gene_NN
expression_NN
and_CC
HIV-1_NN
replication_NN
._.

In_IN
addition_NN
,_,
the_DT
combined_JJ
use_NN
of_IN
anti-Tat_JJ
sFv_NN
intrabodies_NNS
and_CC
the_DT
two_CD
NF-kappa_NN
B_NN
inhibitors_NNS
retained_VBD
the_DT
virus_NN
in_IN
the_DT
latent_JJ
state_NN
for_IN
as_IN
long_JJ
as_IN
45_CD
days_NNS
._.

The_DT
combined_JJ
treatment_NN
resulted_VBD
in_IN
more_RBR
durable_JJ
inhibition_NN
of_IN
HIV-1_NN
replication_NN
than_IN
was_VBD
seen_VBN
with_IN
the_DT
NF-kappa_NN
B_NN
inhibitors_NNS
alone_RB
or_CC
the_DT
anti-Tat_JJ
sFv_NN
intrabodies_NNS
alone_RB
._.

Together_RB
,_,
these_DT
results_NNS
suggest_VBP
that_IN
in_IN
future_JJ
clinical_JJ
gene_NN
therapy_NN
trials_NNS
,_,
a_DT
combined_JJ
pharmacologic_JJ
and_CC
genetic_JJ
strategy_NN
like_IN
the_DT
one_CD
reported_VBN
here_RB
may_MD
improve_VB
the_DT
survival_NN
of_IN
transduced_VBN
cells_NNS
and_CC
prolong_VB
clinical_JJ
benefit_NN
._.

